16 results were returned
With the spread of coronavirus (COVID-19), employers are facing increasingly complex challenges in the day-to-day operation of their businesses. A key issue that many employers are facing is how to stop the disease ...
COVID-19 has had an unprecedented impact on businesses. Many employers have deployed business continuity plans to help mitigate the effect of the virus, which include measures to protect the health and safety of ...
On the tails of the EMA’s Guidance on the Management of Clinical Trials during the COVID-19 pandemic, the Hungarian National Institute of Pharmacy and Nutrition (NIPN) has issued its guidance on how local regulations ...
White Paper for governments on the privacy implications of apps supporting the fight against the COVID-19 pandemic.
Amidst the outbreak of the coronavirus (COVID-19), the Belgian Data Protection Authority ("DPA") has very recently issued guidance on a number of recurring questions concerning the preventive measures taken by companies ...
French data protection law on health research applies to all sponsors, whatever their country of establishment, when they perform clinical trials in France.
As our eyes are all riveted towards the global health crisis and our attention on reorganization of our daily lives accordingly, the risk of cyberattacks is on the rise.
On April 8th 2020, as part of the monitoring of the health crisis linked to Covid-19, Marie-Laure Denis, President of the CNIL, was interviewed by the French Parliament.
The publication of the CNIL’s annual control program is always an important element that the companies should take into consideration to be prepared for it. While the CNIL's on-site inspections will necessarily be ...
Temperature screening and asking about symptoms